For patients with breast cancer, administration of pegfilgrastim 72 hours postchemotherapy reduces pegfilgrastim-induced bone pain (PIBP) compared with administration at 24 and 48 hours, according to a study published online March 24 in the Annals of Internal Medicine.
This article was originally published on MedicalXpress.com

